Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease

Hongtao Liu, MD, PhD, Greg Koval, MS, Greg Malnassy, MS, Pamela Ihonor, MS, Hui Liu, MS, Roger Luo, PhD, Amittha Wickrema, PhD, Steven Dowdy, PhD, Michael Thirman, MD, Koen van Besien, MD, Wendy Stock, MD

Blood (2010) 116 (21): 3921.

https://doi.org/10.1182/blood.V116.21.3921.3921

Published: 2010

Journal Articles

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Sarah Larson, MD, Nicholas Campbell, MD, Dezheng Huo, PhD, Andrew Artz, MD, MS, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, MD, Lucy A Godley, MD, PhD, Elizabeth Shima Rich, MD, PhD, Michael Thirman, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2009) 114 (22): 1048.

https://doi.org/10.1182/blood.V114.22.1048.1048

Published: 2009

Journal Articles

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Vaishalee P. Kenkre, MD, Sarah Horowitz, Richard A. Larson, MD, Andrew Artz, MD, MS, Elizabeth Shima Rich, MD, PhD, Yanming Zhang, M.D., M.S., Michelle M. Le Beau, PhD, Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Michael Thirman, MD, Koen van Besien, MD, Wendy Stock, MD

Blood (2009) 114 (22): 3395.

https://doi.org/10.1182/blood.V114.22.3395.3395

Published: 2009

Journal Articles

Autoregulation of MEIS1 through a Distal Enhancer in Acute Leukemia

Qianfei Wang, PhD, Jingfang Dong, PhD, Ryan Mattison, MD, Shyam Prabhakar, PhD, Fabio Eiji Arimura, Joseph Kaberlein, Chong-zhi Wang, PhD, Qianben Wang, PhD, Marcelo Nobrega, PhD, Michael Thirman, MD

Blood (2008) 112 (11): 745.

https://doi.org/10.1182/blood.V112.11.745.745

Published: 2008

Journal Articles

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Koen W. van Besien, MD, Andrew Artz, MD, Sonali Smith, MD, Elizabeth Rich, MD, Lucy Godley, MD, PhD, Demetria Jones, Paula Del Cerro, RN, Diane Switzer, RN, Brendan Casey, Olatoyosi Odenike, MD, Michael Thirman, MD, Chris Daugherty, MD, Todd M. Zimmerman, MD, Richard Larson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 2321.

https://doi.org/10.1182/blood.V104.11.2321.2321

Published: 2004

Journal Articles

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Daniel A. Pollyea, MD, Andrew S. Artz, MD, MS, Wendy Stock, MD, Sonali M. Smith, MD, Christopher Daugherty, MD, Lucy Godley, MD, PhD, Todd Zimmerman, MD, Olatoyosi M. Odenike, MD, Michael Thirman, MD, Elizabeth Rich, MD, PhD, Richard Larson, MD, Koen Van Besien, MD

Blood (2004) 104 (11): 1145.

https://doi.org/10.1182/blood.V104.11.1145.1145

Published: 2004

NARROW

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Mimetic Peptide to CDK Inhibitor p16 INK4a Induces Cell Death In Mantle Cell Lymphoma Cells: A New Strategy to Eradicate Minimal Residual Disease

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Remission Status and Performance Status, but Not Cytogenetic Risk Group, Are Associated with Outcome After Reduced Intensity Conditioning (RIC) and Allogeneic Hematopoietic Cell Transplantation (HCT) for Therapy-Related Myeloid Neoplasms (t-MN): Results of the University of Chicago Experience.

Autoregulation of MEIS1 through a Distal Enhancer in Acute Leukemia

Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.

Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only